RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:466026

Class I glucose-6-phosphate dehydrogenase deficiency

low confidenceDisorder

Also known as: Class I G6PD deficiency · Severe hemolytic anemia due to G6PD deficiency

Publications

27,058

Trials

0

Interventional, condition-specific

Researchers

1,108

Distinct authors in sample

Gene link

G6PD

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare constitutional hemolytic anemia due to an disorder characterized by severe glucose-6-phosphate dehydrogenase deficiency (typically <10% residual activity) associated with chronic non-spherocytic hemolytic anemia of highly variable severity. Patients are at risk of developing jaundice (potentially leading to kernicterus), gallstones, and reticulocytosis and . They have an increased susceptibility to oxidizing agents provoking episodes of acute hemolysis. Favism, which describes the occurrence of an acute hemolytic reaction in response to the ingestion of fava beans, is more common in infants and young children.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (8)

anemia, congenital, nonspherocytic hemolytic, 1, G6PD deficient · anemia, nonspherocytic hemolytic, due to G6PD deficiency · class I glucose-6-phosphate dehydrogenase deficiency · hemolytic anaemia due to G6PD deficiency · hemolytic anemia due to G6PD deficiency · hemolytic anemia, G6PD deficient (favism), X-linked dominant · severe hemolytic anaemia due to G6PD deficiency · severe hemolytic anemia due to G6PD deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — G6PD

  2. LiteraturePresent

    27,058 matched papers (16,599 in last 10 years) Source

  3. Phenotype characterisedPresent

    15 HPO annotations (e.g. Heinz bodies; Pallor; Decreased circulating glucose-6-phosphate dehydrogenase activity) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (G6PD).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

15

Associated phenotypes · MONDO:0010480

  • Heinz bodies
  • Pallor
  • Decreased circulating glucose-6-phosphate dehydrogenase activity
  • Unconjugated hyperbilirubinemia
  • Reticulocytosis

Showing 5 of 15 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

27,058

27,058 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

27,058 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

16,599 in the last 10 years · low confidence

Phrase hits: 6,813 · MeSH hits: 1

Open Europe PMC search

Who's working on it?

1,108

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Wang L6 papers · 2026

    Department of Prenatal Diagnosis, Lianyungang Maternal and Child Health Hospital, Lianyungang, China.

    Papers in Europe PMC
  2. 02
    Liu S5 papers · 2026

    Jiangsu Provincial Medical Key Laboratory of Fertility Protection and Health Technology Assessment, Jiangsu Health Development Research Center, National Health and Family Planning Commission Contraceptives Adverse Reaction Surveillance Center, Nanjing, China.

    Papers in Europe PMC
  3. 03
    Geck RC4 papers · 2026

    Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA.

    Papers in Europe PMC
  4. 04
    Han Y4 papers · 2026

    Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

    Papers in Europe PMC
  5. 05
    Yang J4 papers · 2026

    Department of Anesthesia, Lishui Municipal Central Hospital, Lishui, China.

    Papers in Europe PMC
  6. 06
    Bancone G3 papers · 2026

    Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Ramat, Tak, Thailand.

    Papers in Europe PMC
  7. 07
    Boonyuen U3 papers · 2026

    Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

    Papers in Europe PMC
  8. 08
    Das S3 papers · 2026

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Vardhman Mahavir Medical college and Safdarjung Hospital, New Delhi, 110029 India.

    Papers in Europe PMC
  9. 09
    Gornsawun G3 papers · 2026

    Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Ramat, Tak, Thailand.

    Papers in Europe PMC
  10. 10
    Huang YC3 papers · 2026

    Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (3)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Class I glucose-6-phosphate dehydrogenase deficiency — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Class I glucose-6-phosphate dehydrogenase deficiency" OR "Class I G6PD deficiency" OR "Severe hemolytic anemia due to G6PD deficiency" OR "anemia, congenital, nonspherocytic hemolytic, 1, G6PD deficient" OR "anemia, nonspherocytic hemolytic, due to G6PD deficiency" OR "hemolytic anaemia due to G6PD deficiency" OR "hemolytic anemia due to G6PD deficiency" OR "hemolytic anemia, G6PD deficient (favism), X-linked dominant" OR "severe hemolytic anaemia due to G6PD deficiency") OR (MESH:"Anemia, Nonspherocytic Hemolytic, Due To G6pd Deficiency") OR ("G6PD" OR "G6PD syndrome" OR "G6PD-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Anemia, Nonspherocytic Hemolytic, Due To G6pd Deficiency

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Class I glucose-6-phosphate dehydrogenase deficiency" OR "Class I G6PD deficiency" OR "Severe hemolytic anemia due to G6PD deficiency" OR "anemia, congenital, nonspherocytic hemolytic, 1, G6PD deficient" OR "anemia, nonspherocytic hemolytic, due to G6PD deficiency" OR "hemolytic anaemia due to G6PD deficiency" OR "hemolytic anemia due to G6PD deficiency" OR "hemolytic anemia, G6PD deficient (favism), X-linked dominant" OR "severe hemolytic anaemia due to G6PD deficiency"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (27058) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T16:57:46.939Z